Safely Transition Patients on Chronic Immune Thrombocytopenia Meds at Home

November 2018

The new med fostamatinib (Tavalisse, TAV-ah-lees) will lead to questions about CHRONIC treatment of immune thrombocytopenia (ITP).

We're familiar with treating most patients with acute ITP using high-dose steroids...IVIG...or both.

If thrombocytopenia persists, splenectomy is typically the next step. But newer data support trying chronic ITP meds first.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote